Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Ads

You May Also Like

Immunovaccine to Present at 2018 BIO CEO & Investor Conference

HALIFAX, Nova Scotia, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs

Board Comprises Six Members with Notable Contributions to the Fields of Oncology and ImmunologyBERKELEY, ...

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results

MORRIS PLAINS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or ...